Bruce Cozadd on drug development
From Building a First-Tier Pharma Culture: Bruce Cozadd CEO of Jazz Pharmaceuticals · · Kinara
“One of my favorite examples of that is when we developed Riley, which we took from pre-clinical all the way through to the market in really record time. We had a pre-IND meeting without a molecule yet... We used to have weekly CMC calls to really talk about what we were doing. Ultimately that product was approved and brought to market before we finished the pivotal clinical trial.”
On , Bruce Cozadd, Co-Founder, Chairman & Chief Executive Officer at JAZZ PHARMACEUTICALS PLC, spoke about drug development during Building a First-Tier Pharma Culture: Bruce Cozadd CEO of Jazz Pharmaceuticals on Kinara.
About Bruce Cozadd
Bruce Cozadd, co-founder, chairman, and CEO of Jazz Pharmaceuticals, has discussed the company's focus on innovation and patient-centric culture in several recent interviews. He stated that the company aims to "innovate in everything we do, not just in R&D," including how they approach patients and make treatments available. Cozadd described the company's culture as centered on people, saying, "my focus is on people, patients as people, and employees as people." He noted that the company rewards behaviors aligned with its values through an honor called "jazz master," which is awarded to employees who are "great ambassadors for our culture." Cozadd has also spoken about the company's approach to drug development, including bringing a lower-sodium version of a chronic medication to market after observing the cardiovascular burden of the original formulation on long-term patients. He cited the development of a product called Riley, which he said was taken "from pre-clinical all the way through to the market in really record time" through collaboration with regulators and the children's oncology group. Cozadd attributed his leadership style to lessons learned from Alejandro Zaffaroni, founder of Alza, where he worked for 10 years.